SCHEMBL3083264

SCHEMBL3083264

OCc1ccc2c(c1)OCCCO2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 4/20 0.50
CD274 Q9NZQ7 4/20 0.50
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
KDM1A O60341 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
HPGD P15428 2/20 0.45
CASP3 P42574 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15853566 0.94 PDCD1 (0.49) PDCD1CD274CYP3A4CYP2D6ALDH1A1
SCHEMBL16472555 0.94 PDCD1 (0.49) PDCD1CD274CYP3A4CYP2D6ALDH1A1
SCHEMBL695934 0.92 PDCD1 (0.57) PDCD1CD274CYP3A4CYP2D6ALDH1A1
SCHEMBL20225729 0.92 PDCD1 (0.57) PDCD1CD274CYP3A4CYP2D6ALDH1A1
SCHEMBL16559901 0.86 MAPT (0.53) PDCD1CD274ALDH1A1GAARAB9A
SCHEMBL18101270 0.86 MAPT (0.53) PDCD1CD274ALDH1A1GAARAB9A
SCHEMBL12764476 0.86 MAPT (0.53) PDCD1CD274ALDH1A1GAARAB9A
SCHEMBL18101275 0.86 MAPT (0.53) PDCD1CD274ALDH1A1GAARAB9A
SCHEMBL14787738 0.86 MAPT (0.53) PDCD1CD274ALDH1A1GAARAB9A
SCHEMBL16472566 0.86 PDCD1 (0.43) PDCD1CD274CYP3A4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 PDCD1 2517/4885CD274 2948/4885CYP3A4 268/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 PDCD1 2608/4885CD274 2966/4885CYP3A4 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.